达美康缓释片在2型糖尿病中的应用

【摘要】 目的比较达美康缓释片与普通剂型达美康疗效、安全性和依从性。方法选取87例2型糖尿病患者,其中达美康缓释片组47例,30～90mg口服,每日1次;普通剂型组40例,40～60mg口服,每日2次。治疗前与治疗12周后分别测量空腹血糖(FBG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1c)并观察低血糖事件,进行临床疗效评定。结果缓释片组和普通剂型组FBG、2hPG、HbA1c在治疗后均有所下降(P<0.05)。低血糖事件两组比较差异无统计学意义(P>0.05)。依从性缓释片组较普通片组好,两组间,差异有统计学意义(P<0.05)。结论达美康缓释片与普通片剂的疗效和安全性相似,但缓释片的依从性较普通片剂佳。更多还原

【Abstract】 Objective To compare the clinical efficacy,safety of Diamicrom sustained-release medicaments and those of ordinary ones,and to observe whether the patients take them on time.MethodsSelect 87 cases of T2DM,47 ones of them were assigned to slow-release Diamicrom,which take once-daily 30 mg to 90 mg.Others were assigned to ordinary Diamicrom,taking twice-daily 80 mg to 120 mg.ResultsThen we mensurated FBG,2hPG,HbA1c and observe cases of hypoglycemia after a 12-week treatment.Then make a clinical efficacy assess.Results Compared with the baseline,FBG,2hPG,HbA1c were significantly reduced in two groups after 12-week treatment(P<0.05).The differences of the amounts of the cases of hypoglycemia between the two groups were not statistically significant.Most cases in slow-release-Diamicrom groups took medicine on time.ConclusionThe clinical efficacy and safety of Diamicrom sustained-release medicaments are similar to those of ordinary ones.But more patients taking slow-release ones can keep to taking them on time.更多还原